Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer

Hyung Soon Park, Minkyu Jung, Hyo Song Kim, Hyoung Il Kim, Ji Yeong An, Jae Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Yong Il Kim, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)


Background: Adjuvant chemotherapy improves survival in patients with gastric cancer. However, the relationship between the timing of adjuvant chemotherapy and survival has not been investigated.

Methods: Patients with D2-resected stage 2 and 3 gastric cancer that received adjuvant chemotherapy from 2005 to 2011 at Yonsei University Health System were included. The patients were grouped according to intervals between surgery and adjuvant chemotherapy.

Results: Among 840 patients, the interval from surgery to the start of adjuvant therapy was less than 4 weeks in 337 (40.1 %) patients (early group), 4–8 weeks in 467 (55.6 %) patients (intermediate group), and more than 8 weeks in 36 (4.3 %) patients (late group). The 5-year RFS was 55.7 % in the early group, 54.4 % in the intermediate group, and 43.6 % in the late group (p = 0.076). The corresponding 5-year OS rates were 63.4, 62.8, and 51.7 % (p = 0.037).

Conclusions: There is insufficient evidence to suggest starting adjuvant chemotherapy within 4 weeks after surgery for patients with D2 resected stage 2 and 3 gastric cancer. However, delayed treatment of adjuvant chemotherapy after 8 weeks showed worse survival outcomes than early and intermediate treatment initiation, suggesting that adjuvant chemotherapy should be considered start within 8 weeks after radical resection.

Original languageEnglish
Pages (from-to)224-231
Number of pages8
JournalAnnals of surgical oncology
Issue number1
Publication statusPublished - 2015

Bibliographical note

Funding Information:
Dr. S.Y. Rha’s research was supported by the Public Welfare & Safety Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2010-0020841). Dr. M. Jung’s research was supported by a grant from the Korea Healthcare technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A101232). We thank Han Na Park (Cancer Metastasis Research Center, Yonsei University College of Medicine) for her help with data collection. Hyung Soon Park, MD and Minkyu Jung, MD, contributed equally to this work as first authors.

Publisher Copyright:
© 2014, Society of Surgical Oncology.

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology


Dive into the research topics of 'Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer'. Together they form a unique fingerprint.

Cite this